Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Alsenaidy, Mohammad A ^a   Jain, Nishant K ^a   Kim, Jae H ^a   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Biophysical; Comparability; Formulation; High throughput; Monoclonal antibodies; Protein; Stability

Indexed keywords

BETA INTERFERON; CETUXIMAB; FIBROBLAST GROWTH FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G1 ANTIBODY; INSULIN; MONOCLONAL ANTIBODY; N GLYCOLOYLNEURAMINIC ACID; NEUTRALIZING ANTIBODY; OLIGOMER; PANITUMUMAB; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SIALIC ACID; TENECTEPLASE; THROMBIN;

ANALYTIC METHOD; ANAPHYLACTIC SHOCK; CHERNOFF FACE DIAGRAM; COMPARATIVE SIGNATURE DIAGRAM; DATA ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPURITY; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; EMPIRAL PHASE DIAGRAM; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; IMMUNOGENICITY; IONIC STRENGTH; ISCHEMIA; NEUTROPENIA; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; PURE RED CELL ANEMIA; REVIEW; THERMOSTABILITY;

EID: 84897951293     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00039     Document Type: Review

References (117)

1. Aggarwal, S. R. (2012). What's fueling the biotech engine-2011 to 2012. Nat. Biotechnol. 30, 1191-1197. doi: 10.1038/nbt.2437.
2. Alsenaidy, M. A., Kim, J. H., Majumdar, R., Weis, D. D., Joshi, S. B., Tolbert, T. J., et al. (2013). High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J. Pharm. Sci. 102, 3942-3956. doi: 10.1002/jps.23730.
3. Alsenaidy, M. A., Wang, T., Kim, J. H., Joshi, S. B., Lee, J., Blaber, M., et al. (2012). An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. Protein Sci. 21, 418-432. doi: 10.1002/pro.2008.
4. Amezcua, C. A., and Szabo, C. M. (2013). Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy. J. Pharm. Sci. 102, 1724-1733. doi: 10.1002/jps.23531.
5. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., and Dwek, R. A. (2007). The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50. doi: 10.1146/annurev.immunol.25.022106.141702.
6. Bakovic, M. P., Selman, M. H. J., Hoffmann, M., Rudan, I., Campbell, H., Deelder, A. M., et al. (2013). High-Throughput IgG Fc N-Glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 12, 821-831. doi: 10.1021/pr300887z.
7. Bal, S. M., Slütter, B., Verheul, R., Bouwstra, J. A., and Jiskoot, W. (2012). Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant-and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 45, 475-481. doi: 10.1016/j.ejps.2011.10.003.
8. Banks, D. D., Latypov, R. F., Ketchem, R. R., Woodard, J., Scavezze, J. L., Siska, C. C., et al. (2012). Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. J. Pharm. Sci. 101, 2720-2732. doi: 10.1002/jps.23219.
9. Beck, A., Sanglier-Cianférani, S., and Van Dorsselaer, A. (2012). Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal. Chem. 84, 4637-4646. doi: 10.1021/ac3002885.
10. Bee, J. S., Randolph, T. W., Carpenter, J. F., Bishop, S. M., and Dimitrova, M. N. (2011). Effects of surfaces and leachables on the stability of biopharmaceuticals. J. Pharm. Sci. 100, 4158-4170. doi: 10.1002/jps.22597.
11. Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., and Jones, G. B. (2012). Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11, 527-540. doi: 10.1038/nrd3746.
12. Boven, K., Knight, J., Bader, F., Rossert, J., Eckardt, K.-U., and Casadevall, N. (2005). Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dial. Transplant. 20(Suppl. 3), iii33-iii40. doi: 10.1093/ndt/gfh1072.
13. Braun, A., Kwee, L., Labow, M., and Alsenz, J. (1997). Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm. Res. 14, 1472-1478. doi: 10.1023/A:1012193326789.
14. Britt, K. A., Schwartz, D. K., Wurth, C., Mahler, H.-C., Carpenter, J. F., and Randolph, T. W. (2012). Excipient effects on humanized monoclonal antibody interactions with silicone oil emulsions. J. Pharm. Sci. 101, 4419-4432. doi: 10.1002/jps.23318.
15. Brooks, S. (2009). Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol. Biotechnol. 43, 76-88. doi: 10.1007/s12033-009-9184-6.
16. Brych, S. R., Gokarn, Y. R., Hultgen, H., Stevenson, R. J., Rajan, R., and Matsumura, M. (2010). Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. J. Pharm. Sci. 99, 764-781. doi: 10.1002/jps.21868.
17. Cauchy, M., and Hefford, M. A. (2010). Excipient exchange in the comparison of preparations of the same biologic made by different manufacturing processes: an exploratory study with recombinant human growth hormone (rhGH). Biologicals 38, 637-643. doi: 10.1016/j.biologicals.2010.07.005.
18. Chirino, A. J., and Mire-Sluis, A. (2004). Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotech. 22, 1383-1391. doi: 10.1038/nbt1030.
19. Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., et al. (2008). Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N. Engl. J. Med. 358, 1109-1117. doi: 10.1056/NEJMoa074943.
20. Cleland, J. L., Powell, M. F., and Shire, S. J. (1993). The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307-377.
21. Committee for Proprietary Medicinal Products. Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance. Non-Clinical and Clinical Issues. EMEA/CPMP/3097/02/Final2003.
22. Cordes, A. A., Carpenter, J. F., and Randolph, T. W. (2012). Accelerated stability studies of abatacept formulations: comparison of freeze-thawing-and agitation-induced stresses. J. Pharm. Sci. 101, 2307-2315. doi: 10.1002/jps.23150.
23. Davies, M. J. (2003). Singlet oxygen-mediated damage to proteins and its consequences. Biochem. Biophys. Res. Commun. 305, 761-770. doi: 10.1016/S0006-291X(03)00817-9.
24. DeFelippis, M. R., and Larimore, F. S. (2006). The role of formulation in insulin comparability assessments. Biologicals 34, 49-54. doi: 10.1016/j.biologicals.2005.08.014.
25. Dellian, M., Yuan, F., Trubetskoy, V. S., Torchilin, V. P., and Jain, R. K. (2000). Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 82, 1513-1518. doi: 10.1054/bjoc.1999.1171.
26. Desaire, H. (2013). Glycopeptide analysis, recent developments and applications. Mol. Cell. Proteomics 12, 893-901. doi: 10.1074/mcp.R112.026567.
27. Dubey, V. K., Lee, J., Somasundaram, T., Blaber, S., and Blaber, M. (2007). Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions. J. Mol. Biol. 371, 256-268. doi: 10.1016/j.jmb.2007.05.065.
28. Expert Committee on Biological Standardization. (2009). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Geneva: World Health Organization.
29. Federici, M., Lubiniecki, A., Manikwar, P., and Volkin, D. B. (2013). Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41, 131-147. doi: 10.1016/j.biologicals.2012.10.001.
30. Food and Drug Administration (1996). Guidance concerning demonstration of comparability of human biological products, availability. Fed. Regist. 61, 18612-18613.
31. Gershon, S. K., Luksenburg, H., Coté, T. R., and Braun, M. M. (2002). Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 346, 1584-1586. doi: 10.1056/NEJM200205163462015.
32. Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., and Varki, A. (2010). Vered Padler-Karavani, Sandra Diaz, and Ajit Varki, Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 28, 863-867. doi: 10.1038/nbt.1651.
33. Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., et al. (2011). High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21, 949-959. doi: 10.1093/glycob/cwr027.
34. Gribben, J. G., Devereux, S., Thomas, N. S. B., Keim, M., Jones, H. M., Goldstone, A. H., et al. (1990). Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335, 434-437. doi: 10.1016/0140-6736(90)90665-R.
35. Hamada, H., Arakawa, T., and Shiraki, K. (2009). Effect of additives on protein aggregation. Curr. Pharm. Biotechnol. 10, 400-407. doi: 10.2174/138920109788488941.
36. Hari, S. B., Lau, H., Razinkov, V. I., Chen, S., and Latypov, R. F. (2010). Acid-Induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry 49, 9328-9338. doi: 10.1021/bi100841u.
37. Harris, R. (2005). Heterogeneity of recombinant antibodies: linking structure to function. Dev. Biol. 122, 117-127.
38. He, F., Hogan, S., Latypov, R. F., Narhi, L. O., and Razinkov, V. I. (2012). High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 99, 1707-1720. doi: 10.1002/jps.21955.
39. He, X. Z., Que, A. H., and Mo, J. J. (2009). Analysis of charge heterogeneities in mAbs using imaged CE. Electrophoresis 30, 714-722. doi: 10.1002/elps.200800636.
40. Hokke, C. H., Bergwerff, A. A., van Dedem, G. W. K., van Oostrum, J., Kamerling, J. P., and Vliegenthart, J. F. G. (1990). Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett. 275, 9-14. doi: 10.1016/0014-5793(90)81427-P.
41. Hong, G., Bazin-Redureau, M. I., and Scherrmann, J. M. G. (1999). Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and fab fragments in rat. J. Pharm. Sci. 88, 147-153. doi: 10.1021/js970335n.
42. Houde, D., Berkowitz, S. A., and Engen, J. R. (2011). The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J. Pharm. Sci. 100, 2071-2086. doi: 10.1002/jps.22432.
43. ICH Q3C. (1996). Stability testing of Biotechnological / Biological products. Fed. Regist. 52, 44928-44935.
44. ICH Q3C. (2003). Impurities-guideline for residual solvents. Fed. Regist. 68, 64352-64353. Available online at: https://www.federalregister.gov/articles/2003/11/13/03-28372/international-conference-on-harmonisation-final-recommendations-on-the-revision-of-the-permitted.
45. ICH Q5E. (2005). Comparability Biotechnological/Biological products subject to changes in their manufacturing process. Fed. Regist. 70, 37861-37862. Available online at: https://www.federalregister.gov/articles/2005/06/30/05-12908/international-conference-on-harmonisation-guidance-on-q5e-comparability-of.
46. Iyer, V., Maddux, N., Hu, L., Cheng, W., Youssef, A. K., Winter, G., et al. (2013). Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J. Pharm. Sci. 102, 43-51. doi: 10.1002/jps.23367.
47. Jiang, H., Wu, S.-L., Karger, B. L., and Hancock, W. S. (2010). Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal. Chem. 82, 6154-6162. doi: 10.1021/ac100956x.
48. Jiskoot, W., Randolph, T. W., Volkin, D. B., Middaugh, C. R., Schöneich, C., Winter, G., et al. (2012). Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J. Pharm. Sci. 101, 946-954. doi: 10.1002/jps.23018.
49. Johnson, R., and Jiskoot, W. (2012). Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J. Pharm. Sci. 101, 3586-3592. doi: 10.1002/jps.23248.
50. Jones, L. S., Kaufmann, A., and Middaugh, C. R. (2005). Silicone oil induced aggregation of proteins. J. Pharm. Sci. 94, 918-927. doi: 10.1002/jps.20321.
51. Kalonia, C., Kumru, O. S., Kim, J. H., Middaugh, C. R., and Volkin, D. B. (2013). Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques. J. Pharm. Sci. 102, 4256-4267. doi: 10.1002/jps.23738.
52. Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., et al. (2007). Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17, 104-118. doi: 10.1093/glycob/cwl057.
53. Khawli, L. A., M. M., Sharifi, J., Hu, P., and Epstein, A. L. (2002). Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1,-2, and-3 monoclonal antibodies after chemical modification with biotin. Cancer Biother. Radiopharm. 17, 359-370. doi: 10.1089/108497802760363150.
54. Kilgore, B. R., Lucka, A. W., Patel, R., Andrien, B. A., and Dhume, S. T. (2008). Comparability and monitoring immunogenic N-linked oligosaccharides from recombinant monoclonal antibodies from two different cell lines using HPLC with fluorescence detection and mass spectrometry. Methods Mol. Biol. 446, 333-346. doi: 10.1007/978-1-60327-084-7_23.
55. Kim, J. H., Iyer, V., Joshi, S. B., Volkin, D. B., and Middaugh, C. R. (2012). Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci. 21, 1540-1553. doi: 10.1002/pro.2144.
56. Kozlowski, S., Woodcock, J., Midthun, K., and Behrman Sherman, R. (2011). Developing the nation's biosimilars program. N. Engl. J. Med. 365, 385-388. doi: 10.1056/NEJMp1107285.
57. Krapp, S., Mimura, Y., Jefferis, R., Huber, R., and Sondermann, P. (2003). Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325, 979-989. doi: 10.1016/S0022-2836(02)01250-0.
58. Kueltzo, L. A., Ersoy, B., Ralston, J. P., and Middaugh, C. R. (2003). Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J. Pharm. Sci. 92, 1805-1820. doi: 10.1002/jps.10439.
59. Lee, J., and Blaber, M. (2009a). The interaction between thermostability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J. Mol. Biol. 393, 113-127. doi: 10.1016/j.jmb.2009.08.026.
60. Lee, J., and Blaber, M. (2009b). Structural basis of conserved cysteine in the fibroblast growth factor family: evidence for a vestigial half-cystine. J. Mol. Biol. 393, 128-139. doi: 10.1016/j.jmb.2009.08.007.
61. Lee, J., and Blaber, M. (2010). Increased functional half-life of fibroblast growth factor-1by recovering a vestigial disulfide bond. J. Proteins Proteomics 1, 37-42. Available online at: http://jpp.org.in/index.php/jpp/article/view/48.
62. Lee, J., and Blaber, M. (2011). Experimental support for the evolution of symmetric protein architecture from a simple peptide motif. Proc. Natl. Acad. Sci. U.S.A. 108, 126-130. doi: 10.1073/pnas.1015032108.
63. Lee, J., Blaber, S. I., Dubey, V. K., and Blaber, M. (2011). A polypeptide "building block" for the beta-trefoil fold identi-ied by "top-down symmetric deconstruction." J. Mol. Biol. 407, 744-763. doi: 10.1016/j.jmb.2011.02.002.
64. Lee, J., Dubey, V. K., Longo, L. M., and Blaber, M. A. (2008). Logical OR redundancy within the Asx-Pro-Asx-Gly type I beta-turn motif. J. Mol. Biol. 377, 1251-1264. doi: 10.1016/j.jmb.2008.01.055.
65. Leymarie, N., and Zaia, J. (2012). Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal. Chem. 84, 3040-3048. doi: 10.1021/ac3000573.
66. Li, C. H., Nguyen, X., Narhi, L., Chemmalil, L., Towers, E., Muzammil, S., et al. (2011). Applications of circular dichroism (CD) for structural analysis of proteins: qualification of near-and far-UV CD for protein higher order structural analysis. J. Pharm. Sci. 100, 4642-4654. doi: 10.1002/jps.22695.
67. Li, C., Rossomando, A., Wu, S.-L., and Karger, B. L. (2013). Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. MAbs 5, 565-575. doi: 10.4161/mabs.24814.
68. Lubiniecki, A., Volkin, D. B., Federici, M., Bond, M. D., Nedved, M. L., Hendricks, L., et al. (2011). Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 39, 9-22. doi: 10.1016/j.biologicals.2010.08.004.
69. Mach, H., Volkin, D. B., Burke, C. J., Middaugh, C. R., Linhardt, R. J., Fromm, J. R., et al. (1993). Nature of the interaction of heparin with acidic fibroblast growth factor. Biochemistry 32, 5480-5489. doi: 10.1021/bi00071a026.
70. Maddux, N. R., Joshi, S. B., Volkin, D. B., Ralston, J. P., and Middaugh, C. R. (2011). Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci. 100, 4171-4197. doi: 10.1002/jps.22618.
71. Maity, H., Lai, Y., Srivastava, A., and Goldstein, J. (2012). Principles and applications of selective biophysical methods for characterization and comparability assessment of a monoclonal antibody. Curr. Pharm. Biotechnol. 13, 2078-2101. doi: 10.2174/138920112802273344.
72. Majhi, P. R., Ganta, R. R., Vanam, R. P., Seyrek, E., Giger, K., and Dubin, P. L. (2006). Electrostatically driven protein aggregation: β-lactoglobulin at low ionic strength. Langmuir 22, 9150-9159. doi: 10.1021/la053528w.
73. Majumdar, R., Manikwar, P., Hickey, J. M., Samra, H. S., Sathish, H. A., Bishop, S. M., et al. (2013). Effects of salts from the hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52, 3376-3389. doi: 10.1021/bi400232p.
74. Manikwar, P., Majumdar, R., Hickey, J. M., Thakkar, S. V., Samra, H. S., Sathish, H. A., et al. (2013). Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J. Pharm. Sci. 102, 2136-2151. doi: 10.1002/jps.23543.
75. Manning, M., Chou, D., Murphy, B., Payne, R., and Katayama, D. (2010). Stability of protein pharmaceuticals: an update. Pharm. Res. 27, 544-575. doi: 10.1007/s11095-009-0045-6.
76. Miller, M. A., Rodrigues, M. A., Glass, M. A., Singh, S. K., Johnston, K. P., and Maynard, J. A. (2013). Frozen-state storage stability of a monoclonal antibody: aggregation is impacted by freezing rate and solute distribution. J. Pharm. Sci. 102, 1194-1208. doi: 10.1002/jps.23473.
77. Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., et al. (2000). The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37, 697-706. doi: 10.1016/S0161-5890(00)00105-X.
78. Moore, W. V., and Leppert, P. (1980). Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51, 691-697. doi: 10.1210/jcem-51-4-691.
79. Murphy, K. (1995). "Noncovalent forces important to the conformational stability of protein structures," in Protein Stability and Folding, Vol. 40, ed B. Shirley (Totowa, NJ: Humana Press), 1-34.
80. Murphy, R. M., and Tsai, A. M. (2006). Misbehaving Proteins: Protein (Mis) Folding, Aggregation, and Stability. New York, NY: Springer.
81. Narhi, L. O., Arakawa, T., Aoki, K. H., Elmore, R., Rohde, M. F., Boone, T., et al. (1991). The effect of carbohydrate on the structure and stability of erythropoietin. J. Biol. Chem. 266, 23022-23026.
82. Narhi, L. O., Schmit, J., Bechtold-Peters, K., and Sharma, D. (2012). Classification of protein aggregates. J. Pharm. Sci. 101, 493-498. doi: 10.1002/jps.22790.
83. Ohkuri, T., Nagatomo, S., Oda, K., So, T., Imoto, T., and Ueda, T. (2010). A Protein's conformational stability is an immunologically dominant factor: evidence that free-energy barriers for protein unfolding limit the immunogenicity of foreign proteins. J. Immunol. 185, 4199-4205. doi: 10.4049/jimmunol.0902249.
84. Pezron, I., Mitra, R., Pal, D., and Mitra, A. K. (2002). Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J. Pharm. Sci. 91, 1135-1146. doi: 10.1002/jps.10114.
85. Pompach, P., Chandler, K. B., Lan, R., Edwards, N., and Goldman, R. (2012). Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search. J. Proteome Res. 11, 1728-1740. doi: 10.1021/pr201183w.
86. Putnam, W. S., Prabhu, S., Zheng, Y., Subramanyam, M., and Wang, Y.-M. C. (2010). Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 28, 509-516. doi: 10.1016/j.tibtech.2010.07.001.
87. Raju, T. S., and Scallon, B. (2007). Fc glycans terminated with N-Acetylglucosamine residues increase antibody resistance to papain. Biotechnol. Prog. 23, 964-971. doi: 10.1002/bp070118k.
88. Raju, T. S., and Scallon, B. J. (2006). Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem. Biophys. Res. Commun. 341, 797-803. doi: 10.1016/j.bbrc.2006.01.030.
89. Reichert, J. M. (2013). Which are the antibodies to watch in 2013. MAbs 5, 1-4. doi: 10.4161/mabs.22976.
90. Robbins, D. C., Cooper, S. M., Fineberg, S. E., and Mead, P. M. (1987). Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36, 838-841. doi: 10.2337/diab.36.7.838.
91. Rosenberg, A. (2006). Effects of protein aggregates: an immunologic perspective. AAPS J. 8, E501-E507. doi: 10.1208/aapsj080359.
92. Rosenberg, A. S., Verthelyi, D., and Cherney, B. W. (2012). Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J. Pharm. Sci. 101, 3560-3567. doi: 10.1002/jps.23244.
93. Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., et al. (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50, 1266-1272. doi: 10.1212/WNL.50.5.1266.
94. Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., et al. (1998). Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15, 641-649. doi: 10.1023/A:1011974512425.
95. Sahin, E., Weiss, W. F., Kroetsch, A. M., King, K. R., Kessler, R. K., Das, T. K., et al. (2012). Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J. Pharm. Sci. 101, 1678-1687. doi: 10.1002/jps.23056.
96. Schellekens, H. (2003). Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Curr. Med. Res. Opin. 19, 433-434. doi: 10.1185/030079903125002072.
97. Schellekens, H. (2008). How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol. Annu. Rev. 14, 191-202. doi: 10.1016/S1387-2656(08)00007-0.
98. Schoenecker, J., Hauck, R., Mercer, M., Parker, W., and Lawson, J. (2000). Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose a1-3Galactose. J. Clin. Immunol. 20, 434-444. doi: 10.1023/A:1026455631876.
99. Seidl, A., Hainzl, O., Richter, M., Fischer, R., Böhm, S., Deutel, B., et al. (2012). Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm. Res. 29, 1454-1467. doi: 10.1007/s11095-011-0621-4.
100. Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., et al. (2002). Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740. doi: 10.1074/jbc.M202069200.
101. Skrlin, A., Radic, I., Vuletic, M., Schwinke, D., Runac, D., Kusalic, T., et al. (2010). Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 38, 557-566. doi: 10.1016/j.biologicals.2010.05.002.
102. Sosic, Z., Houde, D., Blum, A., Carlage, T., and Lyubarskaya, Y. (2008). Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity. Electrophoresis 29, 4368-4376. doi: 10.1002/elps.200800157.
103. Stockert, R. J. (1995). The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75, 591-609.
104. Teska, B. M., Li, C., Winn, B. C., Arthur, K. K., Jiang, Y., and Gabrielson, J. P. (2013). Comparison of quantitative spectral similarity analysis methods for protein higher-order structure confirmation. Anal. Biochem. 434, 153-165. doi: 10.1016/j.ab.2012.11.018.
105. Thirumangalathu, R., Krishnan, S., Ricci, M. S., Brems, D. N., Randolph, T. W., and Carpenter, J. F. (2009). Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J. Pharm. Sci. 98, 3167-3181. doi: 10.1002/jps.21719.
106. Tsai, P. K., Volkin, D. B., Dabora, J. M., Thompson, K. C., Bruner, M. W., Gress, J. O., et al. (1993). Formulation design of acidic fibroblast growth factor. Pharm. Res. 10, 649-659. doi: 10.1023/A:1018939228201.
107. van den Hamer, C. J. A., Morell, A. G., Scheinberg, I. H., Hickman, J., and Ashwell, G. (1970). Physical and chemical studies on ceruloplasmin. J. Biol. Chem. 245, 4397-4402.
108. van Mierlo, G. J., Cnubben, N. H., Wouters, D., Wolbink, G. J., Hart, M. H., Rispens, T., et al. (2013). The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. J. Immunotoxicol. 11, 62-71. doi: 10.3109/1547691X.2013.796023.
109. Wacker, C., Berger, C. N., Girard, P., and Meier, R. (2011). Glycosylation profiles of therapeutic antibody pharmaceuticals. Eur. J. Pharm. Biopharm. 79, 503-507. doi: 10.1016/j.ejpb.2011.06.010.
110. Walsh, G., and Jefferis, R. (2006). Post-translational modifications in the context of therapeutic proteins. Nat. Biotech. 24, 1241-1252. doi: 10.1038/nbt1252.
111. Wang, T., Joshi, S. B., Kumru, O. S., Telikepalli, S., Middaugh, C. R., and Volkin, D. B. (2013b). "Case studies applying biophysical techniques to better characterize protein aggregates and particulates of varying size," in Biophysics for Therapeutic Protein Development, ed L. Narhi (New York, NY: Springer Publishing), 205-243.
112. Wang, T., Kumru, O. S., Yi, L., Wang, Y. J., Zhang, J., Kim, J. H., et al. (2013a). Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment. J. Pharm. Sci. 102, 2520-2537. doi: 10.1002/jps.23645.
113. Wang, W. (2005). Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289, 1-30. doi: 10.1016/j.ijpharm.2004.11.014.
114. Weert, M. D., and Møller, E. (2008). "Immunogenicity of biopharmaceuticals: causes, methods to reduce immunogenicity, and biosimilars," in Immunogenicity of Biopharmaceuticals, Vol. VIII, eds M. D. Weert and E. Møller (New York, NY: Springer), 97-111. doi: 10.1007/978-0-387-75841-1_5.
115. Wuchner, K., Büchler, J., Spycher, R., Dalmonte, P., and Volkin, D. B. (2010). Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J. Pharm. Sci. 99, 3343-3361. doi: 10.1002/jps.22123.
116. Zaia, J. (2008). Mass spectrometry and the emerging field of glycomics. Chem. Biol. 15, 881-892. doi: 10.1016/j.chembiol.2008.07.016.
117. Zheng, K., Bantog, C., and Bayer, R. (2011). The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3, 568-576. doi: 10.4161/mabs.3.6.17922.